SCHEMBL1880904

SCHEMBL1880904

CC(C)C(=O)Nc1[c]cccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 2/20 0.49
TP53 P04637 2/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CETP P11597 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
RAB9A P51151 4/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
LMNA P02545 2/20 0.42
MDM2 Q00987 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GAA P10253 2/20 0.42
ADORA1 P30542 2/20 0.41
NPC1 O15118 3/20 0.39
ADORA3 P0DMS8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16935687 0.87 MDM4 (0.36) MDM4TP53MEN1KMT2AALDH1A1
SCHEMBL7654908 0.86 MDM4 (0.35) MDM4TP53MEN1KMT2AALDH1A1
SCHEMBL7649860 0.86 MDM4 (0.35) MDM4TP53MEN1KMT2AALDH1A1
SCHEMBL28037278 0.86 TAAR1 (0.50)
SCHEMBL8127204 0.86 TAAR1 (0.50)
SCHEMBL7654892 0.86 MDM4 (0.35) MDM4TP53MEN1KMT2AALDH1A1
SCHEMBL7648446 0.86 L3MBTL1 (0.46) MDM4TP53MEN1KMT2AALDH1A1
SCHEMBL8127206 0.86 TAAR1 (0.50)
SCHEMBL28037694 0.83 TAAR1 (0.37) MDM4TP53MEN1KMT2AALDH1A1
SCHEMBL3769268 0.82 ALDH1A1 (0.40) MEN1KMT2AALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303491-A1 Antiviral Drugs for Treatement or Prevention of Dengue Infection SIGA TECHNOLOGIES INC. (US) 2013-11-14 US claimed
US-20100189685-A1 Antiviral Drugs for Treatment or Prevention of Dengue Infection SIGA TECHNOLOGIES, INC. 2010-07-29 US claimed
EP-2148678-A1 ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION Siga Technologies, Inc. (US) 2010-02-03 EP claimed
WO-2008147962-A1 ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION SIGA TECHNOLOGIES, INC. (US) 2008-12-04 WO claimed
US-5807869-A Quinoline derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-09-15 US claimed
US-20160250233-A1 ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION SIGA TECHNOLOGIES, INC. (US) 2016-09-01 US disclosed
US-9353051-B2 Antiviral drugs for treatment or prevention of dengue infection SIGA TECHNOLOGIES, INC. (US) 2016-05-31 US disclosed
US-20130303491-A1 Antiviral Drugs for Treatement or Prevention of Dengue Infection SIGA TECHNOLOGIES INC. (US) 2013-11-14 US disclosed
US-8518960-B2 Antiviral drugs for treatment or prevention of dengue infection SIGA TECHNOLOGIES, INC. (US) 2013-08-27 US disclosed
US-8350995-B2 Optical film, production method of optical film, optically-compensatory film, polarizing plate and liquid crystal display device FUJIFILM CORPORATION (JP) 2013-01-08 US disclosed
CN-101322055-B Retardation film, method for producing retardation film, polarizing plate, and liquid crystal display device KONICA MINOLTA OPTO INC 2012-08-29 CN disclosed
CN-101300307-B Polymer film, method for producing polymer film, optical film and polarizing plate, and liquid crystal display device using the polarizing plate FUJI PHOTO FILM CO LTD 2012-05-09 CN disclosed
EP-0906115-A1 COMBINED USE OF GnRH AGONIST AND ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 1999-04-07 EP disclosed
EP-0876349-A1 QUINOLINE DERIVATIVES AS GNRH ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 1998-11-11 EP disclosed
US-5807869-A Quinoline derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-09-15 US disclosed
WO-1997040846-A1 COMBINED USE OF GnRH AGONIST AND ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-11-06 WO disclosed
EP-0781774-A2 Prolactin production inhibitory agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-07-02 EP disclosed
WO-1997014682-A1 QUINOLINE DERIVATIVES AS GNRH ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-04-24 WO disclosed
US-4392999-A COLORFAST BROWN, RED AND ORANGE CIBA-GEIGY CORPORATION (US) 1983-07-12 US disclosed
US-4229344-A Monazo pigments containing hydroxynaphthoylaminobenzimidazalone radical CIBA-GEIGY CORPORATION (US) 1980-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303491-A1 Antiviral Drugs for Treatement or Prevention of Dengue Infection HAVCR2, EIF2AK2, ZC3HAV1 MDM4 3926/4885TP53 3871/4885MEN1 2863/4885
US-20100189685-A1 Antiviral Drugs for Treatment or Prevention of Dengue Infection EIF2AK2, HAVCR2, SNRPE MDM4 4032/4885TP53 3919/4885MEN1 3401/4885
US-20160250233-A1 ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION EIF2AK2, HAVCR2, SNRPE MDM4 4032/4885TP53 3919/4885MEN1 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.